Table 4.
Clinical data regarding HDR-BT of primary and secondary liver tumors.
| Author | N | n | Entity | Size | Dose | Results | Complications |
|---|---|---|---|---|---|---|---|
| Mohnike et al. (30) | 83 | 140 | Primary (HCC) | 5.8cm (1-15cm) | (15-25Gy) | 12mo OS: 64% | 7.2% major complications |
| 75 | 126 | 4.4cm (1-15cm) | mean: 17.6Gy (15-25Gy) | 36mo OS: 25% | |||
| 12mo LC 95% | |||||||
| Schnapauff et al. (53) | 15 | 15 | Primary (CCC) | 5.25cm (1-18cm) | median: 20Gy (15-20Gy) | Median LC: 10m | 3.7% major complications |
| Median OS: 14mo | |||||||
| Collettini et al. (54) | 35 | 35 | Primary (HCC) | Mean: 7.1cm (5-12cm) | Median: 15Gy (15-20Gy) | 12.5mo LC 92.3% | No complications |
| Collettini et al. (46) | 98 | 212 | Primary (HCC) | Mean: 5cm (1.8-12) | Mean: 16.51Gy (15-20Gy) | 21.1mo LC 91.5% | 0.47% major complications |
| 12mo OS 87.6% | 0.47% minor complications | ||||||
| 24mo OS 57.3% | |||||||
| 36mo OS 41.6% | |||||||
| Denecke et al. (55) | 12 | 12 | Primary (HCC) | Mean: 3.6cm | Mean: 18.9Gy (15-25Gy) | 12mo LC 90% | 8.3% major complications |
| 36mo LC 90% | |||||||
| Jonczyk et al. (56) | 61 | 142 | Primary (CCC) | Median: Subgroup A: 20.41ml (10-38ml) | Mean: 18.42Gy (12-20Gy) | 6mo LC (A:98% B: 89%) | No complications |
| Subgroup B: 69.25ml (40-148ml) | 12mo LC (A: 87% B:78%) | ||||||
| 24mo LC (A: 72% B:37%) | |||||||
| 60mo LC (A: 72% B:37%) | |||||||
| 6mo OS (A:94% B: 75%) | |||||||
| 12mo OS (A: 68% B:63%) | |||||||
| 24mo OS (A: 61% B:36%) | |||||||
| 60mo OS (A: 36% B:12%) | |||||||
| Ricke et al. (25) | 37 | 38 | Primary/Secondary | 4.8cm (2.5-11cm) | mean: 17Gy (10-20Gy) | 9mo LC 73-87% | 5% major complications |
| 12mo OS 69% | 41% minor complications | ||||||
| Ricke et al. (41) | 20 | 20 | Primary/Secondary | 7.7cm (5.5-10.8cm) | mean: 17Gy (12-25Gy) | 6mo LC 80% | 10% major complications |
| 9mo LC 53% | 40% minor complications | ||||||
| 12mo OS 83% | |||||||
| Tselis et al. (57) | 41 | 50 | Primary/Secondary | Median: 84ml (38-1348ml) | Median: 20Gy (7-32Gy) | Primary: 6mo LC 90% | 5% major complications |
| 12mo LC 81% | 15.2% minor complications | ||||||
| 18mo LC 50% | |||||||
| Secondary: | |||||||
| 6mo LC 89% | |||||||
| 12mo LC 73% | |||||||
| 18mo LC 63% | |||||||
| Ricke et al. (11) | 73 | 199 | Colorectal metastases | 5cm (1-13cm) | 3 dose levels (15, 20, 25 Gy) | 15mo LC 75% and 95% if PD > 25Gy | 5% major complications |
| Collettini et al. (58) | 80 | 179 | Colorectal metastases | Mean: 2.85cm (0.8-10.7cm) | Mean: 19.1Gy (15-20Gy) | 12mo LC 88.3% | No major complications |
| 24mo LC 81.2% | |||||||
| 36mo LC 68.4% | |||||||
| 12mo OS 87.6% | |||||||
| 24mo OS 57.3% | |||||||
| 36mo OS 41.6% | |||||||
| Wieners et al. (44) | 41 | 115 | Breast-Ca metastases | Median: 4.4cm (1-11cm) | median: 18.5Gy (12-25Gy) | 6mo LC 97% | 1.4% major complications |
| 12mo LC 93.5% | 8.6% minor complications | ||||||
| 18mo LC 93.5% | |||||||
| 6mo OS 97% | |||||||
| 12mo OS 79% | |||||||
| 18mo OS 60% | |||||||
| Collettini et al. (47) | 37 | 80 | Breast-Ca metastases | Mean: 2.5cm (0.8-7.4cm) | Mean: 18.57Gy (15-20Gy) | 12mo LC: 90% | 2.7% major complications |
| 12mo OS: 96% | |||||||
| Collettini et al. (59) | 7 | 12 | Ovarian-Ca metastases | Mean: 3.19cm (1.3-12cm) | Median: 15Gy | 12mo LC 100% | No complications |
| 12mo OS 100% | |||||||
| Geisel et al. (60) | 8 | 12 | GEAC metastases | Median: 4.6cm (1.4-6.8cm) | Median: 20Gy (15-20Gy) | 8.4mo LC 100% | 11.1% minor complications |
| Schippers et al. (43) | 27 | 52 | NELM | Mean: 3.1cm (0.7cm-11cm) | Median: 20Gy (15-20+Gy) | 12mo LC 92% | 2.5% minor complications |
| 36mo LC 83% | |||||||
| 60mo LC 83% | |||||||
| 12mo OS 96% | |||||||
| 36mo OS 96% | |||||||
| 60mo OS 63% | |||||||
| Geisel et al. (61) | 10 | 16 | RCC metastases | Median: 3.8cm (1-8.2cm) | Median: 20Gy | 12mo LC: 90% | No major complications |
| 12mo OS: 100% | |||||||
| Omari et al. (62) | 14 | 54 | RCC metastases | Mean: 2.9cm (0.7-13.9cm) | Median: 16.1Gy (6.5-27.4Gy) | 10mo LC: 92.6% | No major complications |
| Median OS: 51.2mo | 16.2% minor complications | ||||||
| Wieners et al. (42) | 20 | 49 | Pancreas-Ca metastases | Mean: 2.9cm (1-7.3cm) | Mean: 18.1Gy (15-20Gy) | 12mo LC: 91% | 15% major complications |
| 12mo OS: 45% | |||||||
| Drewes et al. (63) | 16 | 45 | Pancreas-Cametastases | Median: 2.2cm (1-11.2cm) | Median: 21Gy (5-29.1Gy) | Median PFS: 3.4mo | 18% major complications |
| Median OS: 8.9mo | |||||||
| Kieszko et al. (45) | 61 | 73 | Secondary | Median: 42.9ml (2.7-174.9ml) | Mean D90:20.2Gy (15-25Gy) | 6mo LC 88.7% | No major complications |
| 12mo LC 70.7% | 5% minor complications | ||||||
| 6mo OS 96.7% | |||||||
| 12mo OS 79.6% | |||||||
| Kieszko et al. (45) | 61 | 73 | Secondary | Median: 42.9ml (2.7-174.9ml) | Mean D90:20.2Gy (15-25Gy) | 6mo LC 88.7% | No major complications |
| 12mo LC 70.7% | 5% minor complications | ||||||
| 6mo OS 96.7% | |||||||
| 12mo OS 79.6% |
N, number of patients; n, number of lesions; HCC, hepatocellular carcinoma; CCC, cholangiocarcinoma; RCC, renal cell carcinoma; GEAC, gastro-esophageal adenocarcinoma; NELM, neuroendocrine liver metastases; LC, local control; OS, overall survival.